We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+7.28%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$781M
AUM Growth
+$281M
Cap. Flow
+$296M
Cap. Flow %
37.86%
Top 10 Hldgs %
66.38%
Holding
71
New
25
Increased
8
Reduced
8
Closed
25

Top Buys

Rank Stock Value
1
ALXO icon
ALX Oncology
ALXO
+$123M
2
NKTX icon
Nkarta
NKTX
+$60.3M
3
KROS icon
Keros Therapeutics
KROS
+$47.6M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$45.4M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$41.8M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$31.2M
2
BNTX icon
BioNTech
BNTX
+$19.7M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$16.9M
4
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
+$16.7M
5
AKBA icon
Akebia Therapeutics
AKBA
+$16.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INBX
26
DELISTED
Inhibrx, Inc. Common Stock
INBX
$5.61M 0.72%
+311,578
New +$5.65M
LSACU
27
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
$5.44M 0.7%
400,000
– –
PMVP icon
28
PMV Pharmaceuticals
PMVP
$58.7M
$5.33M 0.68%
+150,000
New +$5.52M
PAND
29
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
$5.16M 0.66%
+450,000
New +$7.69M
LRMR icon
30
Larimar Therapeutics
LRMR
$398M
$5.01M 0.64%
330,000
+272,525
+474% +$3.45M
OM icon
31
Outset Medical
OM
$87.5M
$5M 0.64%
+6,667
New +$5.48M
ANNX icon
32
Annexon
ANNX
$814M
$4.83M 0.62%
+159,622
New +$3.74M
PASG icon
33
Passage Bio
PASG
$14.7M
$4.52M 0.58%
17,222
– –
RLAY icon
34
Relay Therapeutics
RLAY
$3.99B
$4.26M 0.55%
+100,000
New +$3.81M
KALV
35
DELISTED
KalVista Pharmaceuticals
KALV
$3.78M 0.48%
300,000
-262,900
-47% -$3.29M
BDTX icon
36
Black Diamond Therapeutics
BDTX
$101M
$3.73M 0.48%
123,465
– –
NARI
37
DELISTED
Inari Medical, Inc. Common Stock
NARI
$3.45M 0.44%
+50,000
New +$3.21M
OBIO icon
38
Orchestra BioMed
OBIO
$231M
$3.3M 0.42%
+300,000
New +$3.37M
PLRX icon
39
Pliant Therapeutics
PLRX
$66.3M
$3.1M 0.4%
136,715
-319,711
-70% -$7.99M
PANA.U
40
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$2.4M 0.31%
+200,000
New +$2.3M
AFIB
41
DELISTED
Acutus Medical Inc
AFIB
$2.23M 0.29%
+75,000
New +$2.28M
CHAQ.U
42
DELISTED
Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of Common Stock, and one
CHAQ.U
$2.11M 0.27%
200,000
– –
TNGX icon
43
Tango Therapeutics
TNGX
$4.34B
$2.07M 0.27%
+200,000
New +$2.04M
FSDC
44
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$1.12M 0.14%
+100,000
New +$1.07M
ARYBU
45
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
$1.1M 0.14%
100,000
– –
RAPT
46
DELISTED
RAPT Therapeutics
RAPT
$1M 0.13%
3,888
-15,487
-80% -$3.44M
AKBA icon
47
Akebia Therapeutics
AKBA
$341M
– –
-1,200,000
Closed -$16.3M
APLT
48
DELISTED
Applied Therapeutics
APLT
– –
-12,600
Closed -$455K
BNTX icon
49
BioNTech
BNTX
$23.4B
– –
-295,000
Closed -$19.7M
ETNB
50
DELISTED
89bio
ETNB
– –
-290,000
Closed -$5.78M
1
2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q3 2020 Portfolio in Review

As of Q3 2020, Logos Global Management held 71 positions worth $781M, up 56% from $500M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Logos Global Management deployed $296M of net new capital in Q3 2020, opening 25 new positions and adding to 8 existing holdings. Its largest new stake was ALX Oncology: 3,136,981 shares worth $118M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was Celldex Therapeutics, an estimated $9.37M trimmed.

  • Logos Global Management's largest Q3 2020 buy was ALX Oncology: 3,136,981 shares worth $118M.
  • Logos Global Management added most to Keros Therapeutics in Q3 2020, an estimated $47.6M increase.
  • Logos Global Management's biggest Q3 2020 reduction was Celldex Therapeutics, cutting an estimated $9.37M.
  • Logos Global Management fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2020, selling an estimated $31.2M.
  • Logos Global Management's ten largest holdings make up 66% of its $781M portfolio in Q3 2020.
  • Logos Global Management opened 25 new positions and closed 25 in Q3 2020.
  • Logos Global Management's portfolio value rose 56% quarter-over-quarter to $781M.

Based on Logos Global Management's 13F filing for Q3 2020, filed 16 Nov 2020.